array:25 [
  "pii" => "S2013251419300057"
  "issn" => "20132514"
  "doi" => "10.1016/j.nefroe.2018.02.017"
  "estado" => "S300"
  "fechaPublicacion" => "2019-01-01"
  "aid" => "477"
  "copyright" => "Sociedad Española de Nefrología"
  "copyrightAnyo" => "2018"
  "documento" => "simple-article"
  "crossmark" => 0
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "cor"
  "cita" => "Nefrologia (English Version). 2019;39:86-8"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1406
    "formatos" => array:3 [
      "EPUB" => 130
      "HTML" => 804
      "PDF" => 472
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:20 [
      "pii" => "S0211699518300420"
      "issn" => "02116995"
      "doi" => "10.1016/j.nefro.2018.02.005"
      "estado" => "S300"
      "fechaPublicacion" => "2019-01-01"
      "aid" => "477"
      "copyright" => "Sociedad Española de Nefrología"
      "documento" => "simple-article"
      "crossmark" => 0
      "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
      "subdocumento" => "cor"
      "cita" => "Nefrologia. 2019;39:86-8"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 2679
        "formatos" => array:3 [
          "EPUB" => 254
          "HTML" => 1710
          "PDF" => 715
        ]
      ]
      "es" => array:10 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Carta al Director</span>"
        "titulo" => "S&#237;ndrome hemol&#237;tico ur&#233;mico at&#237;pico secundario al uso de carfilzomib tratado con eculizumab"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "86"
            "paginaFinal" => "88"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Eculizumab as a treatment for atypical hemolytic syndrome secondary to carfilzomib"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Candela Moliz, Eduardo Guti&#233;rrez, Teresa Cavero, Beatriz Redondo, Manuel Praga"
            "autores" => array:5 [
              0 => array:2 [
                "nombre" => "Candela"
                "apellidos" => "Moliz"
              ]
              1 => array:2 [
                "nombre" => "Eduardo"
                "apellidos" => "Guti&#233;rrez"
              ]
              2 => array:2 [
                "nombre" => "Teresa"
                "apellidos" => "Cavero"
              ]
              3 => array:2 [
                "nombre" => "Beatriz"
                "apellidos" => "Redondo"
              ]
              4 => array:2 [
                "nombre" => "Manuel"
                "apellidos" => "Praga"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2013251419300057"
          "doi" => "10.1016/j.nefroe.2018.02.017"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251419300057?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699518300420?idApp=UINPBA000064"
      "url" => "/02116995/0000003900000001/v1_201901090606/S0211699518300420/v1_201901090606/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:20 [
    "pii" => "S2013251419300045"
    "issn" => "20132514"
    "doi" => "10.1016/j.nefroe.2017.12.006"
    "estado" => "S300"
    "fechaPublicacion" => "2019-01-01"
    "aid" => "470"
    "copyright" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
    "documento" => "simple-article"
    "crossmark" => 0
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "cor"
    "cita" => "Nefrologia &#40;English Version&#41;. 2019;39:88-90"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1304
      "formatos" => array:3 [
        "EPUB" => 124
        "HTML" => 813
        "PDF" => 367
      ]
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
      "titulo" => "Translumbar and transhepatic haemodialysis catheters&#58; A viable option"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "88"
          "paginaFinal" => "90"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Cat&#233;teres translumbares y transhep&#225;ticos para hemodi&#225;lisis&#58; una opci&#243;n viable"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Fig&#46; 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1212
              "Ancho" => 1667
              "Tamanyo" => 98901
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Catheter survival by insertion site&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Juan Rodriguez Mori, Jhony Ramirez Alguiar, Carla Postigo Oviedo, Piero Mora Munares, Manuel Llaro S&#225;nchez, Max Caballero Linares, Manuel Castillo Zegarra"
          "autores" => array:7 [
            0 => array:2 [
              "nombre" => "Juan Rodriguez"
              "apellidos" => "Mori"
            ]
            1 => array:2 [
              "nombre" => "Jhony Ramirez"
              "apellidos" => "Alguiar"
            ]
            2 => array:2 [
              "nombre" => "Carla Postigo"
              "apellidos" => "Oviedo"
            ]
            3 => array:2 [
              "nombre" => "Piero Mora"
              "apellidos" => "Munares"
            ]
            4 => array:2 [
              "nombre" => "Manuel Llaro"
              "apellidos" => "S&#225;nchez"
            ]
            5 => array:2 [
              "nombre" => "Max Caballero"
              "apellidos" => "Linares"
            ]
            6 => array:2 [
              "nombre" => "Manuel Castillo"
              "apellidos" => "Zegarra"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0211699518300353"
        "doi" => "10.1016/j.nefro.2017.12.004"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699518300353?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251419300045?idApp=UINPBA000064"
    "url" => "/20132514/0000003900000001/v1_201903030617/S2013251419300045/v1_201903030617/en/main.assets"
  ]
  "itemAnterior" => array:20 [
    "pii" => "S2013251419300252"
    "issn" => "20132514"
    "doi" => "10.1016/j.nefroe.2018.05.007"
    "estado" => "S300"
    "fechaPublicacion" => "2019-01-01"
    "aid" => "179"
    "copyright" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
    "documento" => "simple-article"
    "crossmark" => 0
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "cor"
    "cita" => "Nefrologia &#40;English Version&#41;. 2019;39:84-6"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1006
      "formatos" => array:3 [
        "EPUB" => 141
        "HTML" => 554
        "PDF" => 311
      ]
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
      "titulo" => "A minimal change disease compatible with C1q nephropathy in a paediatric patient&#46; Evolution and treatment of a difficult pathology"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "84"
          "paginaFinal" => "86"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Enfermedad de cambios m&#237;nimos compatible con nefropat&#237;a C1q en paciente pedi&#225;trico&#46; Evoluci&#243;n y tratamiento de una enfermedad complicada"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Fig&#46; 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 725
              "Ancho" => 1255
              "Tamanyo" => 158158
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; Kidney biopsy&#46; Morphologically&#44; a slight increase in mesangial cells is observed in some glomeruli&#46; &#40;B&#41; Direct immunofluorescence study in which C1q deposits are observed&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Igor Romaniouk Jakovler, Ricardo Mouzo Javier, Carmen Perez Nieto, Antonio Romero, Fernando Simal, Beatriz Casta&#241;on"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "Igor"
              "apellidos" => "Romaniouk Jakovler"
            ]
            1 => array:2 [
              "nombre" => "Ricardo"
              "apellidos" => "Mouzo Javier"
            ]
            2 => array:2 [
              "nombre" => "Carmen"
              "apellidos" => "Perez Nieto"
            ]
            3 => array:2 [
              "nombre" => "Antonio"
              "apellidos" => "Romero"
            ]
            4 => array:2 [
              "nombre" => "Fernando"
              "apellidos" => "Simal"
            ]
            5 => array:2 [
              "nombre" => "Beatriz"
              "apellidos" => "Casta&#241;on"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0211699518300961"
        "doi" => "10.1016/j.nefro.2018.05.004"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699518300961?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251419300252?idApp=UINPBA000064"
    "url" => "/20132514/0000003900000001/v1_201903030617/S2013251419300252/v1_201903030617/en/main.assets"
  ]
  "en" => array:14 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
    "titulo" => "Eculizumab as a treatment for atypical hemolytic uremic syndrome secondary to carfilzomib"
    "tieneTextoCompleto" => true
    "saludo" => "Dear Editor&#44;"
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "86"
        "paginaFinal" => "88"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Candela Moliz, Eduardo Guti&#233;rrez, Teresa Cavero, Beatriz Redondo, Manuel Praga"
        "autores" => array:5 [
          0 => array:4 [
            "nombre" => "Candela"
            "apellidos" => "Moliz"
            "email" => array:1 [
              0 => "candelamoliz&#64;gmail&#46;com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:2 [
            "nombre" => "Eduardo"
            "apellidos" => "Guti&#233;rrez"
          ]
          2 => array:2 [
            "nombre" => "Teresa"
            "apellidos" => "Cavero"
          ]
          3 => array:2 [
            "nombre" => "Beatriz"
            "apellidos" => "Redondo"
          ]
          4 => array:2 [
            "nombre" => "Manuel"
            "apellidos" => "Praga"
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Servicio de Nefrolog&#237;a&#44; Hospital Universitario 12 de Octubre&#44; Madrid&#44; Spain"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "<span class="elsevierStyleItalic">Corresponding author</span>&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "S&#237;ndrome hemol&#237;tico ur&#233;mico at&#237;pico secundario al uso de carfilzomib tratado con eculizumab"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Carfilzomib is a proteasome inhibitor drug with antiproliferative and pro-apoptotic activity&#46; It is one of the drugs used in the treatment of refractory multiple myeloma&#46;<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">1&#8211;4</span></a> The onset of atypical haemolytic uremic syndrome &#40;aHUS&#41; associated with the use of carfilzomib is a complication previously described in the literature&#46;<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">5&#8211;10</span></a> We describe a case of aHUS secondary to carfilzomib effectively treated with eculizumab&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">This case involves a 71-year-old woman with refractory Bence-Jones Kappa multiple myeloma treated with carfilzomib&#44; daratumumab and dexamethasone &#40;KdD&#41;&#46; The patient was admitted to the Haematology Department due to onset of malaise and fever 2 days after receiving the second cycle of KdD&#46; Despite negative microbiology results&#44; her blood pressure increased to over 180&#47;100<span class="elsevierStyleHsp" style=""></span>mmHg on the fourth day&#46; Blood tests found a decrease in haemoglobin of up to 6&#46;8<span class="elsevierStyleHsp" style=""></span>g&#47;dl and in platelets of up to 12&#44;000&#44; with an increase in LDH of up to 900<span class="elsevierStyleHsp" style=""></span>IU&#47;l&#44; accompanied by a deterioration of renal function&#44; with serum creatinine levels of 2&#46;6<span class="elsevierStyleHsp" style=""></span>mg&#47;dl&#46; Suspecting thrombotic microangiopathy &#40;TMA&#41;&#44; treatment with prednisone &#40;1<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;day&#41; and fresh plasma was started&#44; with no improvement&#44; and the patient was referred to the Nephrology Department for assessment&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Studies performed by the Nephrology Department showed 5&#8211;6&#37; schistocytes per field on peripheral blood smear&#44; no signs of malignant arterial hypertension on fundoscopy&#44; undetectable haptoglobin in blood&#44; and negative direct Coombs test&#46; ADAMTS13 test was normal &#40;ADAMTS13<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>50&#37;&#41;&#46; Other causes of aHUS and typical haemolytic uraemic syndrome &#40;<span class="elsevierStyleItalic">STEC-HUS&#41;</span> were ruled out&#44; and genetic studies were not performed due to the high suspicion of a pharmacological cause&#46; Carfilzomib was discontinued and treatment with eculizumab was started after administration of meningococcal prophylaxis with oral penicillin&#46; Plasmapheresis was not performed due to the poor status of the patient and to avoid the comorbidity associated with the technique&#46; One week after the third dose of eculizumab&#44; serum creatinine levels had normalised &#40;1&#46;1<span class="elsevierStyleHsp" style=""></span>mg&#47;dl&#41; without the need for any haemodialysis sessions&#44; and schistocytes had disappeared&#46; From a haematological point of view&#44; partial improvement was observed in haemoglobin and platelet levels&#44; probably due to the underlying disease&#44; although no schistocytes were found&#46; The patient received 3 weekly doses of 900<span class="elsevierStyleHsp" style=""></span>mg of eculizumab&#44; which was discontinued after improvement of renal function and stabilisation of haemolysis parameters&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">Based on the accumulated evidence relating to the pathogenesis of this condition&#44; we wonder whether treatment with eculizumab is justified&#46; In the years since it was released&#44; carfilzomib has been associated with several cases of TMA<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">5&#8211;10</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46; The mechanism by which the damage occurs is thought to be related to the accumulated dose or to an alloimmune effect&#46; Some authors suggest&#44; however&#44; that proteasome inhibitors decrease production of vascular endothelial growth factor &#40;VEGF&#41; by inhibiting the activity of proteins that regulate its genetic transcription&#46; This results in endothelial and podocyte damage similar to that caused by anti-VEGF drugs&#46;<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">6&#44;8</span></a> The latter is the most plausible of the 3 proposed mechanisms&#44; since aHUS has occurred in patients who have only received 2 doses&#44; as in our case&#44; and not in other patients with higher cumulative doses&#46; Likewise&#44; the alloimmune mechanism is an unlikely culprit&#44; given the context of administration of a plasma cell depleting drug in patients that are highly immunosuppressed due to previous chemotherapy and&#44; as in our case&#44; do not respond to immunosuppressive treatment &#40;prednisone&#41;&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">Secondary aHUS should be treated by withdrawing the causative agent&#46;<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">1&#44;2</span></a> In some series&#44; plasmapheresis has been used&#44; with no clear benefit for symptoms&#46;<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">6&#44;7</span></a> In many cases&#44; TMA is resolved by withdrawing the drug&#46; However&#44; as shown by the review published by Cavero et al&#46;&#44; early use of eculizumab may be effective in cases of refractory TMA in which impaired renal function persists or worsens&#44; or in life-threatening situations&#46;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a> Recent studies have shown that the alternative pathway of the complement system is temporarily activated in cases of secondary aHUS&#46; Based on this evidence&#44; the new classification of thrombotic microangiopathies proposed in the KDIGO guidelines<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> now includes all secondary TMAs with ADAMTS13<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#37; activity in the context of aHUS&#46; Therefore&#44; in cases of secondary aHUS that does not improve despite withdrawal of the causative agent&#44; we recommend early&#44; short-term administration of eculizumab&#46;</p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; Moliz C&#44; Guti&#233;rrez E&#44; Cavero T&#44; Redondo B&#44; Praga M&#46; S&#237;ndrome hemol&#237;tico ur&#233;mico at&#237;pico secundario al uso de carfilzomib tratado con eculizumab&#46; Nefrologia&#46; 2019&#59;39&#58;86&#8211;88&#46;</p>"
      ]
    ]
    "multimedia" => array:1 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Reference&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Number of cases&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Clinical presentation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Drug used&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Measure taken&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Outcome&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Chen et al&#46;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">5</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">HUS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Carfilzomib&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Withdrawal of the drug&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Outcome<br>1 Haemodialysis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Yui et al&#46;<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">6</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">HUS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8 Carfilzomib<br>3 Bortezomib&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Withdrawal of the drug<br>4 plasmapheresis<br>3 Eculizumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2 did not recover&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Qaqish et al&#46;<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">7</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">HUS<br>TMA kidney biopsy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Carfilzomib&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Withdrawal of the drug<br>Plasmapheresis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Outcome&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Lodhi et al&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">8</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">HUS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Carfilzomib&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Withdrawal of the drug<br>Plasmapheresis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Outcome&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sullivan et al&#46;<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">9</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">HUS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Carfilzomib&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Withdrawal of the drug&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Outcome&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Hobeika et al&#46;<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">10</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">HTN and proteinuria<br>TMA kidney biopsy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Carfilzomib&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Withdrawal of the drug&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Outcome&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1978548.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Review of cases of TMA associated with the use of carfilzomib&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:10 [
            0 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Atypical hemolytic uremic syndrome and C3 glomerulopathy&#58; conclusions from a &#171;Kidney disease&#58; Improving global outcomes&#187; &#40;KDIGO&#41; controversies Conference"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46;H&#46; Goodship"
                            1 => "H&#46;T&#46; Cook"
                            2 => "F&#46; Fakhouri"
                            3 => "F&#46; Fervenza"
                            4 => "V&#46; Fr&#233;meaux-Bacchi"
                            5 => "D&#46; Kavanagh"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.kint.2016.10.005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Kidney Int"
                        "fecha" => "2017"
                        "volumen" => "91"
                        "paginaInicial" => "539"
                        "paginaFinal" => "551"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27989322"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Eculizumab in secondary atypical haemolytic uraemic syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Cavero"
                            1 => "C&#46; Rabasco"
                            2 => "A&#46; L&#243;pez"
                            3 => "E&#46; Rom&#225;n"
                            4 => "A&#46; &#193;vila"
                            5 => "&#193;&#46; Sevillano"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/ndt/gfw453"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nephrol Dial Transplant"
                        "fecha" => "2017"
                        "volumen" => "32"
                        "paginaInicial" => "466"
                        "paginaFinal" => "474"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28339660"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "STEC-HUS&#44; atypical HUS and TTP are all diseases of complement activation"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "M&#46; Noris"
                            1 => "F&#46; Mescia"
                            2 => "G&#46; Remuzzi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/nrneph.2012.195"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nat Rev Nephrol"
                        "fecha" => "2012"
                        "volumen" => "8"
                        "paginaInicial" => "622"
                        "paginaFinal" => "633"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22986360"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;V&#46; Rajkumar"
                            1 => "M&#46;A&#46; Dimopoulos"
                            2 => "A&#46; Palumbo"
                            3 => "J&#46; Blade"
                            4 => "G&#46; Merlini"
                            5 => "M&#46;V&#46; Mateos"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S1470-2045(14)70442-5"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Oncol"
                        "fecha" => "2014"
                        "volumen" => "15"
                        "paginaInicial" => "e538"
                        "paginaFinal" => "e548"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25439696"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Thrombotic microangiopathy during carfilzomib use&#58; case series in Singapore"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "Y&#46; Chen"
                            1 => "M&#46; Ooi"
                            2 => "S&#46;F&#46; Lim"
                            3 => "A&#46; Lin"
                            4 => "J&#46; Lee"
                            5 => "C&#46; Nagarajan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/bcj.2016.62"
                      "Revista" => array:5 [
                        "tituloSerie" => "Blood Cancer J"
                        "fecha" => "2016"
                        "volumen" => "6"
                        "paginaInicial" => "e450"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27471866"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Proteasome inhibitor associated thrombotic microangiopathy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;C&#46; Yui"
                            1 => "J&#46; van Keer"
                            2 => "B&#46;M&#46; Weiss"
                            3 => "A&#46;J&#46; Waxman"
                            4 => "M&#46;B&#46; Palmer"
                            5 => "V&#46;D&#46; D&#8217;Agati"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/ajh.24447"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Hematol"
                        "fecha" => "2016"
                        "volumen" => "91"
                        "paginaInicial" => "E348"
                        "paginaFinal" => "E352"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27286661"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Carfilzomib&#58; a cause of drug associated thrombotic microangiopathy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "I&#46; Qaqish"
                            1 => "I&#46;M&#46; Schlam"
                            2 => "H&#46;A&#46; Chakkera"
                            3 => "R&#46; Fonseca"
                            4 => "J&#46; Adamski"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.transci.2016.03.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Transfus Apher Sci"
                        "fecha" => "2016"
                        "volumen" => "54"
                        "paginaInicial" => "401"
                        "paginaFinal" => "404"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27017313"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Thrombotic microangiopathy associated with proteasome inhibitors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46; Lodhi"
                            1 => "A&#46; Kumar"
                            2 => "M&#46;U&#46; Saqlain"
                            3 => "M&#46; Suneja"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/ckj/sfv059"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Kidney J"
                        "fecha" => "2015"
                        "volumen" => "8"
                        "paginaInicial" => "632"
                        "paginaFinal" => "636"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26413293"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "M&#46;R&#46; Sullivan"
                            1 => "A&#46;V&#46; Danilov"
                            2 => "F&#46; Lansigan"
                            3 => "N&#46;M&#46; Dunbar"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/jca.21371"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Apher"
                        "fecha" => "2015"
                        "volumen" => "30"
                        "paginaInicial" => "308"
                        "paginaFinal" => "310"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25413611"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "L&#46; Hobeika"
                            1 => "S&#46;E&#46; Self"
                            2 => "J&#46;C&#46; Velez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/1471-2369-15-156"
                      "Revista" => array:5 [
                        "tituloSerie" => "BMC Nephrol"
                        "fecha" => "2014"
                        "volumen" => "15"
                        "paginaInicial" => "156"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25267524"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000003900000001/v1_201903030617/S2013251419300057/v1_201903030617/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35436"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Letters to the Editor"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003900000001/v1_201903030617/S2013251419300057/v1_201903030617/en/main.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251419300057?idApp=UINPBA000064"
]
Share
Journal Information
Vol. 39. Issue. 1.January - February 2019
Pages 1-110
Vol. 39. Issue. 1.January - February 2019
Pages 1-110
Letter to the Editor
Open Access
Eculizumab as a treatment for atypical hemolytic uremic syndrome secondary to carfilzomib
Síndrome hemolítico urémico atípico secundario al uso de carfilzomib tratado con eculizumab
Visits
7297
Candela Moliz
Corresponding author
candelamoliz@gmail.com

Corresponding author.
, Eduardo Gutiérrez, Teresa Cavero, Beatriz Redondo, Manuel Praga
Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, Spain
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Tables (1)
Table 1. Review of cases of TMA associated with the use of carfilzomib.
Full Text
Dear Editor,

Carfilzomib is a proteasome inhibitor drug with antiproliferative and pro-apoptotic activity. It is one of the drugs used in the treatment of refractory multiple myeloma.1–4 The onset of atypical haemolytic uremic syndrome (aHUS) associated with the use of carfilzomib is a complication previously described in the literature.5–10 We describe a case of aHUS secondary to carfilzomib effectively treated with eculizumab.

This case involves a 71-year-old woman with refractory Bence-Jones Kappa multiple myeloma treated with carfilzomib, daratumumab and dexamethasone (KdD). The patient was admitted to the Haematology Department due to onset of malaise and fever 2 days after receiving the second cycle of KdD. Despite negative microbiology results, her blood pressure increased to over 180/100mmHg on the fourth day. Blood tests found a decrease in haemoglobin of up to 6.8g/dl and in platelets of up to 12,000, with an increase in LDH of up to 900IU/l, accompanied by a deterioration of renal function, with serum creatinine levels of 2.6mg/dl. Suspecting thrombotic microangiopathy (TMA), treatment with prednisone (1mg/kg/day) and fresh plasma was started, with no improvement, and the patient was referred to the Nephrology Department for assessment.

Studies performed by the Nephrology Department showed 5–6% schistocytes per field on peripheral blood smear, no signs of malignant arterial hypertension on fundoscopy, undetectable haptoglobin in blood, and negative direct Coombs test. ADAMTS13 test was normal (ADAMTS13>50%). Other causes of aHUS and typical haemolytic uraemic syndrome (STEC-HUS) were ruled out, and genetic studies were not performed due to the high suspicion of a pharmacological cause. Carfilzomib was discontinued and treatment with eculizumab was started after administration of meningococcal prophylaxis with oral penicillin. Plasmapheresis was not performed due to the poor status of the patient and to avoid the comorbidity associated with the technique. One week after the third dose of eculizumab, serum creatinine levels had normalised (1.1mg/dl) without the need for any haemodialysis sessions, and schistocytes had disappeared. From a haematological point of view, partial improvement was observed in haemoglobin and platelet levels, probably due to the underlying disease, although no schistocytes were found. The patient received 3 weekly doses of 900mg of eculizumab, which was discontinued after improvement of renal function and stabilisation of haemolysis parameters.

Based on the accumulated evidence relating to the pathogenesis of this condition, we wonder whether treatment with eculizumab is justified. In the years since it was released, carfilzomib has been associated with several cases of TMA5–10 (Table 1). The mechanism by which the damage occurs is thought to be related to the accumulated dose or to an alloimmune effect. Some authors suggest, however, that proteasome inhibitors decrease production of vascular endothelial growth factor (VEGF) by inhibiting the activity of proteins that regulate its genetic transcription. This results in endothelial and podocyte damage similar to that caused by anti-VEGF drugs.6,8 The latter is the most plausible of the 3 proposed mechanisms, since aHUS has occurred in patients who have only received 2 doses, as in our case, and not in other patients with higher cumulative doses. Likewise, the alloimmune mechanism is an unlikely culprit, given the context of administration of a plasma cell depleting drug in patients that are highly immunosuppressed due to previous chemotherapy and, as in our case, do not respond to immunosuppressive treatment (prednisone).

Table 1.

Review of cases of TMA associated with the use of carfilzomib.

Reference  Number of cases  Clinical presentation  Drug used  Measure taken  Outcome 
Chen et al.5  HUS  Carfilzomib  Withdrawal of the drug  Outcome
1 Haemodialysis 
Yui et al.6  11  HUS  8 Carfilzomib
3 Bortezomib 
Withdrawal of the drug
4 plasmapheresis
3 Eculizumab 
2 did not recover 
Qaqish et al.7  HUS
TMA kidney biopsy 
Carfilzomib  Withdrawal of the drug
Plasmapheresis 
Outcome 
Lodhi et al.8  HUS  Carfilzomib  Withdrawal of the drug
Plasmapheresis 
Outcome 
Sullivan et al.9  HUS  Carfilzomib  Withdrawal of the drug  Outcome 
Hobeika et al.10  HTN and proteinuria
TMA kidney biopsy 
Carfilzomib  Withdrawal of the drug  Outcome 

Secondary aHUS should be treated by withdrawing the causative agent.1,2 In some series, plasmapheresis has been used, with no clear benefit for symptoms.6,7 In many cases, TMA is resolved by withdrawing the drug. However, as shown by the review published by Cavero et al., early use of eculizumab may be effective in cases of refractory TMA in which impaired renal function persists or worsens, or in life-threatening situations.2 Recent studies have shown that the alternative pathway of the complement system is temporarily activated in cases of secondary aHUS. Based on this evidence, the new classification of thrombotic microangiopathies proposed in the KDIGO guidelines1 now includes all secondary TMAs with ADAMTS13>10% activity in the context of aHUS. Therefore, in cases of secondary aHUS that does not improve despite withdrawal of the causative agent, we recommend early, short-term administration of eculizumab.

References
[1]
T.H. Goodship, H.T. Cook, F. Fakhouri, F. Fervenza, V. Frémeaux-Bacchi, D. Kavanagh, et al.
Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a «Kidney disease: Improving global outcomes» (KDIGO) controversies Conference.
Kidney Int, 91 (2017), pp. 539-551
[2]
T. Cavero, C. Rabasco, A. López, E. Román, A. Ávila, Á. Sevillano, et al.
Eculizumab in secondary atypical haemolytic uraemic syndrome.
Nephrol Dial Transplant, 32 (2017), pp. 466-474
[3]
M. Noris, F. Mescia, G. Remuzzi.
STEC-HUS, atypical HUS and TTP are all diseases of complement activation.
Nat Rev Nephrol, 8 (2012), pp. 622-633
[4]
S.V. Rajkumar, M.A. Dimopoulos, A. Palumbo, J. Blade, G. Merlini, M.V. Mateos, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, et al.
Lancet Oncol, 15 (2014), pp. e538-e548
[5]
Y. Chen, M. Ooi, S.F. Lim, A. Lin, J. Lee, C. Nagarajan, et al.
Thrombotic microangiopathy during carfilzomib use: case series in Singapore.
Blood Cancer J, 6 (2016), pp. e450
[6]
J.C. Yui, J. van Keer, B.M. Weiss, A.J. Waxman, M.B. Palmer, V.D. D’Agati, et al.
Proteasome inhibitor associated thrombotic microangiopathy.
Am J Hematol, 91 (2016), pp. E348-E352
[7]
I. Qaqish, I.M. Schlam, H.A. Chakkera, R. Fonseca, J. Adamski.
Carfilzomib: a cause of drug associated thrombotic microangiopathy.
Transfus Apher Sci, 54 (2016), pp. 401-404
[8]
A. Lodhi, A. Kumar, M.U. Saqlain, M. Suneja.
Thrombotic microangiopathy associated with proteasome inhibitors.
Clin Kidney J, 8 (2015), pp. 632-636
[9]
M.R. Sullivan, A.V. Danilov, F. Lansigan, N.M. Dunbar.
Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.
J Clin Apher, 30 (2015), pp. 308-310
[10]
L. Hobeika, S.E. Self, J.C. Velez.
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
BMC Nephrol, 15 (2014), pp. 156

Please cite this article as: Moliz C, Gutiérrez E, Cavero T, Redondo B, Praga M. Síndrome hemolítico urémico atípico secundario al uso de carfilzomib tratado con eculizumab. Nefrologia. 2019;39:86–88.

Copyright © 2018. Sociedad Española de Nefrología
Download PDF
Idiomas
Nefrología (English Edition)
Article options
Tools